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Abstract: Minimally invasive treatment options are an important part of the uterine 
fibroid-treatment arsenal, especially among younger patients and in those who plan future 
pregnancies. This article provides an overview of the currently available minimally inva-
sive therapy options, with a special emphasis on a completely noninvasive option: magnetic 
resonance-guided focused ultrasound (MRgFUS). In this review, we describe the background 
of MRgFUS, the patient-selection criteria for MRgFUS, and how the procedure is performed. 
We summarize the published clinical trial results, and review the literature on pregnancy 
post-MRgFUS and on the cost-effectiveness of MRgFUS.
Keywords: uterine fibroids, MRgFUS, focused ultrasound, minimally invasive treatment
Introduction
In women of reproductive age, uterine fibroids (leiomyomas or myomas) are the 
most common single indication for hysterectomy,1 and account for significant health 
care costs.2 Current medical treatment options of uterine fibroids range from medical 
management (gonadotropin-releasing hormone [GnRH] therapy) to myomectomy, or 
to complete hysterectomy.3–5 The noninvasive option of magnetic resonance-guided 
focused ultrasound (MRgFUS) is becoming increasingly accepted, with over 9,880 
patients treated to date worldwide with one system (ExAblate 2100, InSightec, Tirat 
Carmel, Israel). This treatment option is important in light of the fact that women are 
increasingly seeking less invasive alternatives to a classic surgical intervention and 
seeking procedures that offer shorter recovery times with the possibility of fertility 
preservation.6,7 Another important driving force in the development and widespread 
application of less invasive fibroid therapy is the reduction in treatment-associated 
health care cost.8,9 The purpose of this article is to summarize the literature to date on 
MRgFUS as a promising option for uterine fibroid treatment.
Uterine fibroids
The estimated incidence of uterine fibroids is approximately 70% in Caucasian 
females over 50 years of age, and is over 80% in African American females.2,10,11 
While some patients are completely asymptomatic, approximately 25% are symp-
tomatic and experience pelvic pain and/or pressure, menorrhagia or dysmenorrhagia, 
increased frequency of urination, or reproductive dysfunction.12,13 Fibroids are clas-
sified by their location in the uterus as subserosal, intramural, or submucosal. They 
can be pedunculated from either the serosal surface or from the mucosal surface. 
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Histologically, uterine fibroids are benign, hormone-sensitive 
smooth-muscle tumors mixed with fibrous connective tissue, 
demarcated from the surrounding tissue by a pseudocapsule. 
Fibroids can undergo hyaline degeneration or hemorrhagic 
infarction, and they may calcify as they regress after meno-
pause. The goal of fibroid treatment is relief of symptoms, 
such as bleeding, pelvic pressure, or pain.6,13 Historically, 
the first-line treatment of uterine fibroids has been surgical 
intervention (hysterectomy or myomectomy). For women 
who desire fertility preservation, myomectomy has been a 
preferable option. Less invasive treatment options are avail-
able, such as uterine artery embolization (UAE), MRgFUS, 
or less common thermal ablation therapies using laser, 
radiofrequency, and cryoablation.6,14 Medical therapy using 
hormone-based treatment is also available,15 but may have 
a rebound effect once discontinued.16 Hormone therapy is 
often used in patients who present with heavy menstruation 
or as a presurgical adjunct for those with large fibroids, as 
they reduce the endometrial hyperplasia associated with the 
fibroid (progestogens) and induce the shrinkage of the fibroid 
(GnRH-antagonist effect).16
Surgical therapeutic options – 
hysterectomy and myomectomy
For perimenopausal women with symptomatic fibroids who 
are family-complete, hysterectomy (the surgical removal of 
the uterus) is an effective treatment. Uterine fibroids remain 
the most common indication for hysterectomy in the US.6,14 
However, hysterectomy is a major operation, and can cause 
significant disability for 2 months postoperatively.17,18 The 
mortality rate is 0.38–1 per 1,000 patients, significant com-
plications develop in 3% of patients, and minor complications 
are experienced by up to 30% of patients.17–19 The long-term 
consequences of hysterectomy may include urinary inconti-
nence and early ovarian failure,20,21 in addition to the potential 
psychological consequences of the uterus removal.22 There 
is an increased trend of women desiring pregnancies later 
in their reproductive age, and as such there is an increased 
demand for conservative treatment of fibroids. An alternative 
to hysterectomy is an open or laparoscopic myomectomy. 
Open myomectomy results in high patient satisfaction, and 
approximately 80% of patients report alleviation in their 
symptoms;23 however, recovery can take 6–8 weeks.24,25 
Patients who undergo open myomectomy are usually 
younger, weigh less, are of lower parity, and have smaller 
fibroids and uterus size compared to patients who undergo 
hysterectomy.23 The most common side effects are fever and 
hemorrhage in both procedures.19
When pregnancy is desired and the uterus is small 
(,5 cm) with a small number (fewer than three) of fibroids, 
laparoscopic myomectomy can be considered.1,26 Smaller 
fibroids (3–8 cm) can be removed from the uterus via a lap-
aroscopic approach (for intramural and subserosal fibroids) 
or a hysteroscopic approach (for submucosal fibroids). Sev-
eral studies have shown that laparoscopic myomectomy is 
associated with shorter hospital stay, less postoperative pain, 
and reduced blood loss compared to hysterectomy and open 
myomectomy.27–30 Removal of larger fibroids in this fashion 
is more difficult, and a common surgical strategy has been the 
use of morcellation. However, of recent times, the US Food 
and Drug Administration (FDA) has recommended against the 
use of this technique.31,32 As indicated on the FDA website, 
[the] FDA discourages use of laparoscopic power morcella-
tion for removal of uterus or uterine fibroids. The procedure 
poses the risk of spreading undetected cancerous tissue in 
women with unsuspected cancer.
If morcellation is banned, a new management strategy for 
larger uterine fibroids may have to be considered.31,32
Small (,5 cm) submucosal fibroids may be accessible by 
hysteroscopic removal. After cervical dilatation, the hystero-
scope is inserted transvaginally into the uterine cavity, the 
cavity is insufflated, and after careful inspection, the fibroid 
can be removed.33
Minimally invasive nonsurgical 
therapies
Uterine artery embolization
UAE was introduced in 1995, and is widely used and 
accepted for the treatment of uterine fibroids.34–36 Absolute 
contraindications to the procedure are pregnancy, active 
infection, or suspected malignancy (uterine, cervical, or 
adnexal). Relative contraindications are coagulopathy, 
severe contrast allergy, or renal impairment.37 The procedure 
involves catheterization of a femoral artery, through which 
the uterine artery is accessed. Embolization is brought about 
through bilateral intra-arterial infusion of microparticles, 
producing blockage in the arterial blood flow to the uterus. 
UAE treatment efficacy is high, the patients’ symptoms 
improve in 80%–90% of cases, and the median duration 
of hospital stay and recovery times are shorter compared 
with hysterectomy.38,39 The major complication rate is low 
(1%–4%).17,19,39 The rate of hysterectomy for major complica-
tions postprocedure is 1.1%–1.5%.17,40 Other complications 
of UAE are postprocedural pain, ovarian failure, and aller-
gic reaction to the injected compound.41–45 Over time, the 
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rate of complications after UAE has been decreasing, with 
greater operation experience and technical advancement.39 
The overall failure and recurrence rate in patients who were 
enrolled in the Fibroid registry, which looked at long-term 
outcomes after UAE, was 20% at 5 years.46
Image-guided thermal therapies
Thermal ablation occurs when there is a rapid change in 
the local tissue temperature (.55°C for heat and ,-20°C 
to -50°C for cold) in response to the targeted therapy. Imag-
ing is critically important in thermal ablation. It provides 
information on tumor detection, characterization, and guid-
ance for treatment targeting. Currently, MR imaging (MRI) 
is the only modality that is able to provide such information 
and guidance, including reliable real-time quantitative tem-
perature measurements. Current minimally invasive thermal 
ablation techniques include laser, cryo-, and radiofrequency 
ablation (RFA).
Laser ablation of uterine fibroids
Laser ablation of the fibroids can be performed through 
a laparoscopic or endoscopic route (since 1989), or as a 
percutaneous (since 1999) treatment with the assistance of 
MRI guidance.47–49 The treatment uses interstitial laser pho-
tocoagulation, which applies a low-power laser to destroy 
the fibroid tissue, guided by thermal monitoring. It uses a 
1,064 nm-wavelength laser that penetrates deep into tissue. 
Laparoscopic or hysteroscopic laser ablation has been shown 
to decrease fibroid volume by 50%–70%.47,48
Cryotherapy
Cryoablation is an ablation technique that damages tissues by 
rapid freezing and rapid thawing using high-pressure argon 
gas (temperature -20°C to -50°C). The temperature change 
leads to vascular stasis, thrombosis, and ultimately local tissue 
ischemia. As a result, the cell membranes rupture and the cells 
die. Cryoablation of the fibroid can take place through a laparo-
scopic or hysteroscopic approach. Since the early 2000s, it has 
been performed with MRI guidance. The reduction of the mean 
fibroid size ranges between 31% and 80%. The postprocedural 
complications can include fever and infection.50–52
Radiofrequency ablation
RFA was first used for fibroid treatment in 2005 through a 
laparoscopic approach.53–56 Ultrasound or CT (computerized 
tomography) scan is used to guide the procedure. Since RFA 
is incompatible with MRI, there is no reliable way to monitor 
the local temperature or to estimate the true ablation area. The 
advantage of RFA over cryoablation is that a larger ablation 
area (up to 6 cm in diameter) can be achieved in a reasonable 
time (~30 minutes). No major complications are associated 
with RFA; in some cases, spotting bleeding can last up to 8 
weeks postablation.57
Noninvasive therapeutic option 
for uterine fibroid treatment: 
magnetic resonance-guided focused 
ultrasound surgery
Milestones in the development of MRgFUS
Wood and Loomis, who are often called the “fathers of 
ultrasonics”, were the first to describe that US has a biologic 
effect on living tissues in the 1920s.58 In 1942, Lynn et al 
proposed the use of FUS to induce thermal or mechanical 
effects at a focal location in living tissue.59 Subsequently, the 
Fry brothers built a clinical FUS device to treat hyperkinetic 
diseases, such as Parkinson’s disease in the 1950s.60,61 In the 
1980s, FUS was introduced as a treatment option for glau-
coma, and the FDA approved the first FUS system (Sonocare 
CST-100) to treat glaucoma shortly thereafter.62 Hynynen 
et al and others introduced MRgFUS in the 1990s.63–65 It con-
tained a single geometrically focused transducer adopted to 
perform in a high-field-strength MR magnet.63–65 In the 2000s, 
the first MRI-compatible phased array and its driving system 
were introduced to create a larger treated volume of tissue, 
and to deliver sonication in different locations by steering the 
US beam from one target to the next. In the same time period, 
MRI-based thermal dosimetry was developed for guidance 
and for confirmation of thermal delivery.66–70
In 2004, the ExAblate 2000 system (InSightec) received 
FDA clearance for fibroid treatments. Currently, there are 
two FDA-approved MRgFUS platforms: the ExAblate 2000 
and the ExAblate 2100 (InSightec). Sonalleve MR-HIFU 
(Philips Healthcare, Andover, MA, USA) is another system 
approved in Europe. Since its introduction to the market 
in 2004, the ExAblate systems have treated 9,880 patients 
to date (10,527 uterine fibroids; information provided by 
InSightec). MRgFUS has also been used as a palliative 
treatment of bone metastases, breast fibroadenomas, breast 
cancer, brain tumors, and liver disease.71–73
Patient selection for MRgFUS
One of the first steps in selecting patients for MRgFUS 
treatment is to determine symptomatology and confirm 
the presence of uterine fibroids, as other conditions (such 
as adenomyosis) can cause similar symptomatology. 
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At our institution, all suitable candidates complete the 
symptom-severity score (SSS) of the Uterine Fibroid 
Symptoms and Quality of Life (UFS-QOL) questionnaire, 
a validated instrument for assessing symptoms specific 
for quality of life due to uterine fibroids.74 The SSS of the 
UFS-QOL is a 100-point scale composed of eight ques-
tions, assessing symptoms related to bleeding and bulk- or 
volume-related complaints. The score is significantly higher 
in women with symptomatic fibroids. This objective scoring 
system is used for preprocedure evaluation and postproce-
dure monitoring.
All eligible candidates undergo a contrast-enhanced MRI 
to determine fibroid signal intensity, size, number, and loca-
tion (Table 1). The optimal scenario for MRgFUS treatment 
is a solitary fibroid #10 cm in diameter, of low signal inten-
sity on T2-weighted images on MRI, enhances on contrast 
images, and is accessible by the MRgFUS system (ie, ,12 
cm from margin of the skin; ExAblate 2000/2100) (Figure 1). 
Therefore, fibroids that do not demonstrate adequate enhance-
ment or have areas of peripheral calcification (Figure 2) 
may not be good candidates. Fibroids that are too small and 
multiple in number (Figure 3) and without a dominant can-
didate for targeting are not suitable for MRgFUS either. As 
multiple sonications are needed to destroy the desired fibroid 
volume, treatment volume is limited by the treatment time 
that is realistically feasible for the patient. The total treatment 
time for a 7–8 cm fibroid (depending on energy absorption 
and location) is ~3 hours of MRgFUS ablation. Larger 
fibroids may require significantly longer treatment. In addi-
tion, fibroids that are of high signal intensity on T2-weighted 
images (Figure 4) may indicate cellular fibroids, which can 
be difficult to obtain an optimal temperature increase in.75–78 
It is possible that pretreatment with a GnRH agonists may 
help “dry out” these fibroids ahead of time, allowing for 
higher-temperature deposition at treatment.
For larger fibroids, pretreatment with GnRH agonists may 
allow for fibroid shrinkage, which can result in shortened 
treatment times. Overall, by reducing vascularity, energy 
deposition can be potentiated. Therefore, GnRH-agonist 
treatment prior to MRgFUS will increase efficacy.4,79 On the 
other hand, the absence of enhancement in contrast imaging 
may indicate nonperfused and necrotic tissue, in which case 
the patient may not benefit from the MRgFUS treatment. 
While fibroid number and size are important to consider, so 
also is fibroid location. If pedunculated and subserosal, there 
is a risk of amputation of the fibroid from the uterus.80
There are physical limitations of each MRgFUS system. 
For example, the ExAblate system allows sonications to be 
delivered up to 12 cm vertical distance from the skin of the 
anterior abdominal wall. As the goal of treatment is to target 
as much of the fibroid as possible (up to 100%), fibroids 
where not all tissue is accessible may not have as good an 
Table 1 MR imaging findings that require evaluation on the screening MR and on the planning MR on treatment day
Finding Possible limitation Possible remediation
Size Too small Poor treatment effect
Too large (.10 cm) Poor treatment effect Consider GnRH agonist prior  
to MRgFUS
Location Too posterior (.12 cm from the 
center of the fibroid to abdominal wall)
,4 cm to sacrum
Limited beam penetration
Heating of sacrum and causing 
sciatic nerve injury
Treatment is planned to maximize  
the angle of incidence between  
the beam and the sacrum (ie, tilt beam 
down toward the legs)
Submucosal or subserosal (especially 
pedunculated)
Risk of expulsion Consider endoscopic treatment
Fibroid character Degenerated (nonperfusion) Poor treatment effect
Calcification Reflection of beam/possible  
deposition of heat proximal  
to calcification
Hypercellular (high signal on T2WI) Difficulty in heat deposition Consider GnRH agonist prior  
to MRgFUS
Acoustic window Abdominal scar May deviate ultrasound  
wave/skin burn
Treatment is planned to angle  
the ultrasound beam and avoid  
passing through scar
Intervening visceral organ  
(bladder or bowel)
Visceral organ damage Angle ultrasound beam/displace  
the bowel with rectal gel/urinary  
bladder distention
Abbreviations: GnRH, gonadotropin-releasing hormone; MRgFUS, magnetic resonance-guided focused ultrasound; T2WI, T2-weighted image.
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outcome. Also, if the fibroid is too close to the sacrum, the 
heating of the sacral bone may lead to sciatic nerve injury.81 
Therefore, fibroids that are close to the lumbosacral plexus 
or to bone surfaces should only be considered suitable for 
MRgFUS if there is at least 4 cm distance between the fibroid 
and the bone surface.81
Treatment procedure
Preparation for the procedure
After fasting overnight, the patient arrives at the outpatient 
MRI suite. The patient’s abdomen has to be clean of any type 
of lotion or cream, as even small amount of these products 
can cause skin burn during treatment. The abdomen is shaved 
between the umbilicus and 1 cm below the pubic bone, a 
urinary catheter is placed into the bladder, and an intravenous 
line is sited for administration of conscious sedation.
Treatment planning
The MRgFUS is planned and performed with the patient in a 
prone position (Figure 5). The patient lies on a custom-built 
patient-scanner table, which houses all of the electronics 
and the phased array transducer in a sealed water bath. This 
table docks to the magnet. To ensure good acoustic coupling 
with the patient’s abdomen, a gel pad is placed between the 
transducer and the patient’s skin. A mixture of degassed water 
and US gel is applied to both sides of the gel pad to avoid air 
bubbles. Multiplanar T2-weighted images are taken of the 
pelvis, and are transferred to the ExAblate/Sonalleve plan-
ning program. The region of treatment is manually drawn and 
defined within the capsule of the fibroid. The target volume 
is analyzed with superimposed US-beam paths in all three 
planes. By angling the beam path, the target can be optimally 
accessed and unwanted heating can be avoided. When bowel 
Figure 1 Sagittal MRI of a typical case pre/post treatment.
Notes: (A) Sagittal T2-weighted image (T2WI) demonstrating a single uterine fibroid of predominantly low signal intensity, accessible by the ultrasound transducer, which is 
imbedded in the magentic resonance table. (B) Sagittal T1-weighted image (T1WI) postcontrast at screening demonstrates heterogeneous enhancement of the fibroid. (C) 
Sagittal T1WI postadministration of intravenous contrast after MRgFUS treatment demonstrates lack of enhancement in the fibroid, consistent with treatment effect.
Abbreviations: MRgFUS, magnetic resonance-guided focused ultrasound; MRI, magnetic resonance image.
Figure 2 Examples of MRgFUS screen failures.
Notes: (A) Sagittal T1-weighted image (T1WI) prior to contrast demonstrates area of very low signal along the inferior margin of the fibroid. (B) After administration of 
contrast agent, there is lack of enhancement in the majority of the fibroid, and the clumpy areas of low signal are again seen. Both of these factors – lack of enhancement 
and clumpy low signal areas consistent with peripheral calcifications – are reasons for screen failure for an MRgFUS treatment. (C) Sagittal T1WI postadministration of 
intravenous contrast in a different case demonstrating complete lack of enhancement in two uterine fibroids; this case was also a screen failure.
Abbreviation: MRgFUS, magnetic resonance-guided focused ultrasound.
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loops are found beneath the abdominal wall, they can usually 
be moved out of the beam path by distending the bladder with 
saline or using large gel pads on the abdomen wall to apply 
external pressure.75,81
Procedure
Just prior to the procedure being started, titrated doses of 
fentanyl and midazolam are administered intravenously to 
alleviate anxiety and relieve pain. The patient, however, 
should remain conscious, responsive, and able to give feed-
back throughout the procedure. The MRgFUS procedure 
starts with low-power sonications (50–100 W). Real-time 
thermometry is performed through the proton-resonance fre-
quency-shift method.66,69 Sonication location is determined, 
and the targeting accuracy can be confirmed. If the targeting 
is accurate, additional sonications are delivered at thera-
peutic power level to confirm the appropriate thermometry. 
The goal of the treatment is to increase the local temperature 
in the selected tissue volume over 60°C, which ensures coag-
ulative necrosis in the tissue.81,82 Between each sonication, 
adequate cooling time is ensured to avoid thermal buildup 
and damage to normal tissues: the ExAblate 2100 and the 
Sonalleve systems do this calculation automatically, and they 
apply subsequent sonications in a relatively distant place to 
allow adequate cooling time for the tissue. The procedure 
continues with delivery of all planned sonications. During 
the treatment, to ensure no complications occur, continuous 
communication with the patient is very important.
At the end of the MRgFUS treatment, we assess the 
treatment effect by measuring the nonperfused volume 
(NPV) of fibroid tissue on gadolinium contrast-enhanced 
T1-weighted images. Higher NPV ratios are associated with 
lower probabilities of recurrence, due to fibroid regrowth and 
a reduced need for additional procedures.76–78,83
Figure 3 Example of MRgFUS screen failure due to innumerable small fibroids.
Notes: (A) Axial, (B) coronal, and (C) sagittal T2-weighted image of a patient with innumerable, small uterine fibroids, without a definite dominant fibroid. Cases such as 
these are not good candidates for MRgFUS.
Abbreviation: MRgFUS, magnetic resonance-guided focused ultrasound.
Figure 4 Illustrative example of cellular fibroid.
Notes: (A) Axial, (B) coronal, and (C) sagittal T2-weighted image (T2WI) demonstrating a fibroid of high signal intensity on T2WI. These fibroids are thought to represent 
very cellular fibroids, and may be difficult to treat.
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Obstacles in the FUS-beam path
US energy is absorbed to a greater extent by high-density 
tissues as abdominal wall scar tissue, and is reflected 
by low-density tissues (eg, containing air), such as the 
intestines or the air-containing catheter in the bladder.84,85 
In some cases, the angulation (tilting the beam path away) 
of the US-beam path can help to avoid these tissues. Alter-
natively, the bladder can be filled with saline to enable the 
beam to pass through the bladder. The presence of bowel 
loops behind the anterior abdominal wall and in front of the 
uterus fibroids can sometimes be manipulated by filling the 
bladder with saline and filling the rectum with US gel, and 
displacing the bowel loops to create a sonication window 
(Figure 6).
Clinical trial results
The initial Phase I/II trial of the ExAblate 2000 device was 
conducted to evaluate the safety and feasibility of MRgFUS.86 
In this trial, premenopausal women with symptomatic 
fibroids, defined by their SSS from the UFS-QOL question-
naire, were recruited. Treatment was limited to 100 mL of 
fibroid tissue, a 15 mm safety margin from both the serosal 
surface and the endometrium of the uterus, and 2 hours of 
sonication. In this trial, all patients went to a planned hys-
terectomy within 1 month, allowing for direct pathological 
correlations. It was demonstrated that MRgFUS could suc-
cessfully cause thermal coagulation and necrosis in uterine 
fibroids.
Subsequently, a multicenter Phase III clinical trial was 
carried out to evaluate the effectiveness and durability of 
the treatment.82,87,88 In this trial, patients did not receive any 
additional forms of therapy after MRgFUS. Enrollment 
criteria included symptomatic fibroids in patients who had 
no desire for further pregnancy. The patients were followed, 
and the outcome was documented using the UFS-QOL ques-
tionnaire scores at 6, 12, and now 24 months after treatment, 
and by fibroid volume on MRI. In 2004, after receiving FDA 
clearance, the treatment guidelines were changed to allow a 
Figure 5 Photograph depicting a patient lying in the prone position on the magnetic 
resonance (MR) table.
Notes: The focused ultrasound transducer array is located within the MR table, and 
the patient is positioned such that the fibroid overlies the ultrasound transducer. 
Reprinted with permission from InSightec Inc.
Figure 6 Illustrative example of manipulation of beam path obstruction.
Notes: (A) Screening sagittal T2-weighted image (T2WI) and (B) axial T2WI of an accessible solitary uterine fibroid, which demonstrated enhancement postadministration 
of intravenous contrast agent on sagittal and axial T1 postcontrast images (C, D). However, on the day of treatment, sagittal localizing images demonstrated multiple bowel 
loops anterior to the uterus (E). The bowel loops were manipulated by filling the bladder with saline and filling the rectum with ultrasound gel (F, sagittal localizer), which 
displaced the bowel loops superiorly to create a sonication window. After the bladder was emptied, the sonication window remained (G, sagittal localizer), allowing for 
satisfactory treatment (H, sagittal T1-weighted image (T1WI) postadministration of contrast agent) with a large area of nonenhancement.
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treatment volume of 150 mL per fibroid, with no restriction 
on the distance from the endometrium. Fennessy et al82 first 
analyzed the effect of the different protocols on treatment 
results, and found that the relaxed treatment protocol resulted 
in a greater NPV, with 25.79% achieved versus the 16.65% 
of the restricted protocol (P,0.001).82 For those treated with 
the restricted protocol, clinical follow-up revealed that 74% 
of patients at 6 months and 73% at 12 months had a greater 
than 10-point improvement in symptom score. In those 
treated according to the more relaxed protocol, 88% reported 
a 10-point or greater symptom improvement at 6 months, and 
91% had significant symptom improvement at 12 months. 
This study was the first to show that treating a greater amount 
of fibroid tissue resulted in a larger treatment volume and 
better symptom improvement and durability.
This need for increased NPVs and better outcomes has 
been replicated in multiple papers since then.77,83,89–91 In all, 
these papers underscore that the learning process and the 
worldwide accumulation of data on MRgFUS of uterine 
fibroids has led to treatment optimization to safely achieve 
large-enough NPVs that will ensure sustained clinical 
benefit.
MRgFUS as a treatment option for 
African–American women
Uterine fibroids have a disproportionate impact on 
African–American (AA) women. They have an earlier 
age of onset with more symptomatic fibroids than non-AA 
women,92–94 with different effects on employment and ther-
apy-seeking behavior.95 A recent study by our group found 
that AA women tended to have differences in the pattern 
of fibroid disease, with a higher total number of fibroids 
that were of smaller volume, compared to non-AA women 
(Figure 3).96 Specific to MRgFUS, AA patients were more 
likely to fail screening than non-AA patients, ie, they were 
more likely to be unsuitable candidates for MRgFUS. This 
was more likely to be due to MRI findings that indicated that 
safe delivery of treatment was not possible, such as significant 
anterior abdominal wall scarring or multiple small fibroids. 
However, once AA patients pass screening and were treated 
with MRgFUS, the two groups do not differ in terms of their 
need for surgical intervention for failed MRgFUS treatment 
and in terms of their overall symptom improvement and 
fibroid shrinkage.
MRgFUS and fertility and pregnancy
Early clinical trials and initial treatment protocols of MRgFUS 
included only women who were family-complete.87,88 In recent 
years, there have been several case reports of successful 
pregnancies following MRgFUS treatment,97–104 which are 
summarized in a recent review article by Clark et al.105 As 
MRgFUS does not target the uterus, it remains intact, and 
anecdotal pregnancies are to be expected. Rabinovici et al 
published the largest case study results of 54 pregnancies 
in 51 patients who received MRgFUS on average 8 months 
before conception.98 The term-delivery rate was reported to 
be 93%, and the C-section rate was remarkably lower than 
that seen after UAE.106–108 In addition, it is notable that in 
this series, there were neither low-birth-weight infants nor 
stillbirths, which have been reported (albeit at a low fre-
quency) in women who become pregnant post-UAE. While 
women who conceive after MRgFUS should be informed that 
normal pregnancy outcomes and normal vaginal deliveries 
are possible, since our knowledge is currently limited, these 
pregnancies need to be followed up carefully.
Technical improvements
In recent years, different approaches have been developed 
to increase the treatment volume and decrease the treatment 
time of MRgFUS. In the early treatments, the sonications 
were delivered at one or a small number of treatment depths 
in a grid pattern.86 The tissue was allowed to cool back to 
baseline before a subsequent sonication was performed, in 
order to avoid accumulation of heating in the near field due 
to overlap of the US beam. This need to take time for cooling 
limited the time available for treatment, and thus reduced 
overall efficacy. Optimization of placement of focal spots 
to avoid accumulated heating in the near field has greatly 
improved the treatment time. The systems have also evolved 
so that larger areas can be ablated during each sonication by 
electronically steering the US beam over a larger area. The 
ExAblate system steers the focal beam laterally to increase 
the width of the focal area, and when in “elongated” mode 
it steers the focal beam from a deeper to a more shallow 
location over the course of the sonication. For large fibroids, 
this steering in the depth direction can cover several centi-
meters in one sonication. Improved robotics and the ability 
to disable portions of the array that place unwanted tissue 
in the US-beam path have also been developed with the aim 
of increasing the patient population that are candidates for 
MRgFUS.
The Sonalleve system uses volumetric heating with 
real-time feedback. This sonication approach is based on the 
work of Salomir et al and Mougenot et al109,110 and utilizes 
heat diffusion by electrically steering the focal point in a 
predetermined circular path in the focal plane. Over time, 
the center of the “treatment cell” is filled in via thermal con-
duction and perfusion. To control the temperature increase 
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in each sonication location, the Sonalleve system uses the 
feature “real-time thermometry feedback”, by which it can 
automatically modify the sonication parameters to generate a 
spatially controlled temperature profile at the target location. 
The combination of the volumetric ablation and the real-time 
multislice temperature monitoring provides well-controlled 
maximum lesion temperature, predictable lesion volumes, 
and faster ablation of larger fibroids.111
Cost-effectiveness
As discussed, studies have concluded that MRgFUS is safe 
and effective in shrinking fibroids and producing symptom 
relief. It is a short outpatient procedure, and there are few 
adverse events or minor complications associated with it. 
However, according to the Blue Cross and Blue Shield 
technology assessment of MRgFUS for treatment of uterine 
fibroids,112 MRgFUS is still considered investigational, with-
out sufficient proof that it “improves the net health outcome 
for any clinical application”, and currently not all insurance 
companies cover MRgFUS for uterine fibroid treatment. 
To address this assessment, there have been a number of 
cost-effectiveness analyses performed that have compared 
MRgFUS with conventional treatments for fibroids.113–115
O’Sullivan et al found MRgFUS to be in the range of 
currently accepted criteria for cost-effectiveness, along with 
hysterectomy and UAE, while Zowall et al found that a treat-
ment strategy for symptomatic uterine fibroids starting with 
MRgFUS is likely to be cost-effective.113,114 Our group found 
that MRgFUS, as the first-line treatment for symptomatic 
fibroids, is preferred over both UAE and hysterectomy from 
a cost-effectiveness standpoint.115 Fennessy et al applied 
specific short-term quality-of-life decreases (“disutilities”) 
related to MRgFUS, UAE, and hysterectomy, for the cost-
effectiveness analyses.116 This approach strengthened our 
results, as we took into account the difference in the quality 
of life and duration of recovery following each specific treat-
ment procedure for uterine fibroids.
Conclusion
To determine the value and effectiveness of MRgFUS in 
the widely available therapeutic options for uterine fibroids, 
one can consider the feasibility studies that have proven the 
safety and efficacy of MRgFUS (which eventually led the 
FDA approval of this technology), together with multicenter 
clinical trial results that showed the treatment’s efficacy in 
symptom reduction and resolution with the low occurrence 
rate of side or adverse effects. As the technology advances 
and improves, and the operators become more aware of how 
to circumvent anatomical obstacles, such as bowel and scar 
tissue, MRgFUS treatment time is decreasing and more 
patients become treatment-eligible. Recent studies have 
indicated that MRgFUS is a safe and effective treatment 
option in AA women, in whom this disease is more com-
mon and more symptomatic. Preliminary evidence would 
suggest that MRgFUS is not a definitive roadblock to future 
pregnancies, although this is an area that will require more 
exploration for confirmation. Furthermore, cost-effectiveness 
studies have concluded that MRgFUS is cost-effective as a 
uterine-sparing, noninvasive therapy for eligible patients. 
As MRgFUS continues to mature and undergo technical 
improvements, we believe that it will be a first-choice therapy 
for many women and an important tool in the personalized 
therapy arsenal for uterine fibroids.
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